Transmembrane TNF-A preferentially expressed by leukemia stem cells and blasts is a potent target for antibody therapy

Blood

Volumn 126, Issue 12, 2015, Pages 1433-1442

  Zhou, Xiaoxi ^a   Zhou, Shiqiu ^a   Li, Baihua ^b   Li, Qinlu ^a   Gao, Lili ^a   Li, Dan ^a   Gong, Quan ^a   Zhu, Li ^a   Wang, Jue ^a   Wang, Na ^a   Huang, Liang ^a   Zhao, Lei ^a   Li, Zhuoya ^b   Zhou, Jianfeng ^a  

^a Tongji Hospital   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; COMPLEMENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE PROGRESSION; CELL HOMING; CELL MEMBRANE; CELL PROLIFERATION; CELL SURFACE; CELL SURVIVAL; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG POTENCY; DRUG SENSITIVITY; GENE EXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; JURKAT CELL LINE; LEUKEMIA CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MIDDLE AGED; MOUSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT DURATION; TUMOR ENGRAFTMENT; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; COMPLEMENT SYSTEM PROTEINS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942921940     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-624833     Document Type: Article

References (32)

1. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-Alpha from cells. Nature. 1997;385(6618):729-733.
2. Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets. 2008;8(2):124-131.
3. Barak V, Nisman B, Polliack A. The tumor necrosis factor family and correlation with disease activity and response to treatment in hairy cell leukemia. Eur J Haematol. 1999;62(2):71-75.
4. Foa R, Massaia M, Cardona S, et al. Production of tumor necrosis factor-Alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease. Blood. 1990;76(2):393-400.
5. Kagoya Y, Yoshimi A, Kataoka K, et al. Positive feedback between NF-kB and TNF-A promotes leukemia-initiating cell capacity. J Clin Invest. 2014;124(2):528-542.
6. Tsimberidou AM, Estey E, Wen S, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer. 2008; 113(7):1605-1613.
7. Volk A, Li J, Xin J, et al. Co-inhibition of NF-kB and JNK is synergistic in TNF-expressing human AML. J Exp Med. 2014;211(6):1093-1108.
8. Gallipoli P, Pellicano F, Morrison H, et al. Autocrine TNF-A production supports CML stem and progenitor cell survival and enhances their proliferation. Blood. 2013;122(19):3335-3339.
9. Brown ER, Charles KA, Hoare SA, et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-Alpha inhibitor, in patients with advanced cancer. Ann Oncol. 2008; 19(7):1340-1346.
10. Cohen RB, Dittrich KA. Anti-TNF therapy and malignancy - A critical review. Can J Gastroenterol. 2001;15(6):376-384.
11. Egberts JH, Cloosters V, Noack A, et al. Antitumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res. 2008; 68(5):1443-1450.
12. Harrison ML, Obermueller E, Maisey NR, et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: Two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol. 2007;25(29):4542-4549.
13. Madhusudan S, Foster M, Muthuramalingam SR, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res. 2004;10(19):6528-6534.
14. Yu M, Zhou X, Niu L, et al. Targeting transmembrane TNF-A suppresses breast cancer growth. Cancer Res. 2013;73(13):4061-4074.
15. Wang N, Huang L, Wang D, et al. Successful engraftment of human acute lymphoblastic leukemia cells in NOD/SCID mice via intrasplenic inoculation. Cancer Biol Ther. 2012;13(12): 1158-1164.
16. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004;5(7):738-743.
17. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006; 12(10):1167-1174.
18. Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
19. Yan D, Qin N, Zhang H, et al. Expression of TNFalpha leader sequence renders MCF-7 tumor cells resistant to the cytotoxicity of soluble TNF-Alpha. Breast Cancer Res Treat. 2009;116(1):91-102.
20. Bernt KM, Armstrong SA. Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol. 2009;46(1):33-38.
21. Nakayama J, Ogawa Y, Yoshigae Y, et al. A humanized anti-human Fas antibody, R-125224, induces apoptosis in type I activated lymphocytes but not in type II cells. Int Immunol. 2006;18(1):113-124.
22. Kikushige Y, Shima T, Takayanagi S, et al. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell. 2010;7(6):708-717.
23. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood. 2004;104(9):2919-2925.
24. Cox CV, Martin HM, Kearns PR, Virgo P, Evely RS, Blair A. Characterization of a progenitor cell population in childhood T-cell acute lymphoblastic leukemia. Blood. 2007;109(2):674-682.
25. Chen H, Xiao L, Zhang H, et al. The involvement of b-Actin in the signaling of transmembrane TNF-A-mediated cytotoxicity. J Leukoc Biol. 2011; 89(6):917-926.
26. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15(17):5323-5337.
27. Grivennikov SI, Karin M. Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis. 2011;70(suppl 1): i104-i108.
28. Gu L, Findley HW, Zhu N, Zhou M. Endogenous TNFalpha mediates cell survival and chemotherapy resistance by activating the PI3K/Akt pathway in acute lymphoblastic leukemia cells. Leukemia. 2006;20(5):900-904.
29. Ardestani S, Li B, Deskins DL, Wu H, Massion PP, Young PP. Membrane versus soluble isoforms of TNF-A exert opposing effects on tumor growth and survival of tumor-Associated myeloid cells. Cancer Res. 2013;73(13): 3938-3950.
30. Balkwill F. TNF-Alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25(3):409-416.
31. Sethi G, Sung B, Aggarwal BB. TNF: A master switch for inflammation to cancer. Front Biosci. 2008;13:5094-5107.
32. Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol. 2013;230(3): 241-248.